JP2018503644A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503644A5 JP2018503644A5 JP2017537500A JP2017537500A JP2018503644A5 JP 2018503644 A5 JP2018503644 A5 JP 2018503644A5 JP 2017537500 A JP2017537500 A JP 2017537500A JP 2017537500 A JP2017537500 A JP 2017537500A JP 2018503644 A5 JP2018503644 A5 JP 2018503644A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- treatment
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15151488 | 2015-01-16 | ||
| EP15151488.2 | 2015-01-16 | ||
| PCT/EP2016/050804 WO2016113404A1 (en) | 2015-01-16 | 2016-01-15 | Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503644A JP2018503644A (ja) | 2018-02-08 |
| JP2018503644A5 true JP2018503644A5 (https=) | 2019-02-14 |
| JP7274258B2 JP7274258B2 (ja) | 2023-05-16 |
Family
ID=52354814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017537500A Active JP7274258B2 (ja) | 2015-01-16 | 2016-01-15 | リキシセナチドを用いた小児２型真性糖尿病患者の治療 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20160235818A1 (https=) |
| EP (1) | EP3244912B1 (https=) |
| JP (1) | JP7274258B2 (https=) |
| KR (1) | KR102614574B1 (https=) |
| CN (1) | CN107405386A (https=) |
| AR (1) | AR103415A1 (https=) |
| AU (1) | AU2016207964B2 (https=) |
| CL (1) | CL2017001843A1 (https=) |
| CR (1) | CR20170376A (https=) |
| EA (1) | EA035423B1 (https=) |
| ES (1) | ES2895513T3 (https=) |
| IL (1) | IL253460B (https=) |
| MX (1) | MX381944B (https=) |
| PH (1) | PH12017501290A1 (https=) |
| PL (1) | PL3244912T3 (https=) |
| PT (1) | PT3244912T (https=) |
| SG (1) | SG11201705755UA (https=) |
| TN (1) | TN2017000292A1 (https=) |
| TW (1) | TWI706779B (https=) |
| WO (1) | WO2016113404A1 (https=) |
| ZA (1) | ZA201704512B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102256618A (zh) | 2008-10-17 | 2011-11-23 | 赛诺菲-安万特德国有限公司 | 胰岛素和glp-1激动剂的组合 |
| NZ599847A (en) | 2009-11-13 | 2013-09-27 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| PE20171622A1 (es) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | Formulacion de relacion fija de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| DE102019129444A1 (de) * | 2019-10-31 | 2021-05-06 | Lts Lohmann Therapie-Systeme Ag | Lagtime-Verkürzung/Eisspray |
| US12179064B2 (en) * | 2021-04-11 | 2024-12-31 | Vikas Khurana | System, apparatus and method for training a subject |
| WO2024133412A1 (en) | 2022-12-21 | 2024-06-27 | Novo Nordisk A/S | Methods and systems for estimating fbg value from cgm data |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
| EP2435061A4 (en) * | 2009-05-28 | 2013-03-27 | Amylin Pharmaceuticals Inc | DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS |
| DK2324853T3 (en) * | 2009-11-13 | 2015-11-30 | Sanofi Aventis Deutschland | Lixisenatide as an add-on to metformin to treat diabetes type 2 |
| US9821032B2 (en) * | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| CN107693782A (zh) * | 2011-05-13 | 2018-02-16 | 赛诺菲-安万特德国有限公司 | 用于治疗2型糖尿病患者的利西拉来和二甲双胍 |
| US20130090285A1 (en) * | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| AR087693A1 (es) * | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| MX359329B (es) * | 2011-10-28 | 2018-09-25 | Sanofi Aventis Deutschland | Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2. |
-
2016
- 2016-01-14 TW TW105101028A patent/TWI706779B/zh active
- 2016-01-14 US US14/995,910 patent/US20160235818A1/en not_active Abandoned
- 2016-01-14 AR ARP160100087A patent/AR103415A1/es unknown
- 2016-01-15 WO PCT/EP2016/050804 patent/WO2016113404A1/en not_active Ceased
- 2016-01-15 MX MX2017009294A patent/MX381944B/es unknown
- 2016-01-15 KR KR1020177022646A patent/KR102614574B1/ko active Active
- 2016-01-15 TN TNP/2017/000292A patent/TN2017000292A1/en unknown
- 2016-01-15 CN CN201680016033.2A patent/CN107405386A/zh active Pending
- 2016-01-15 EP EP16700758.2A patent/EP3244912B1/en active Active
- 2016-01-15 EA EA201791611A patent/EA035423B1/ru not_active IP Right Cessation
- 2016-01-15 AU AU2016207964A patent/AU2016207964B2/en active Active
- 2016-01-15 PL PL16700758T patent/PL3244912T3/pl unknown
- 2016-01-15 ES ES16700758T patent/ES2895513T3/es active Active
- 2016-01-15 CR CR20170376A patent/CR20170376A/es unknown
- 2016-01-15 SG SG11201705755UA patent/SG11201705755UA/en unknown
- 2016-01-15 JP JP2017537500A patent/JP7274258B2/ja active Active
- 2016-01-15 PT PT16700758T patent/PT3244912T/pt unknown
-
2017
- 2017-07-04 ZA ZA2017/04512A patent/ZA201704512B/en unknown
- 2017-07-13 IL IL253460A patent/IL253460B/en unknown
- 2017-07-14 PH PH12017501290A patent/PH12017501290A1/en unknown
- 2017-07-14 CL CL2017001843A patent/CL2017001843A1/es unknown
-
2019
- 2019-02-04 US US16/266,873 patent/US20190365864A1/en not_active Abandoned
-
2020
- 2020-09-22 US US17/028,400 patent/US20210187075A1/en not_active Abandoned
-
2023
- 2023-08-07 US US18/366,130 patent/US20240173384A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503644A5 (https=) | ||
| HRP20161620T1 (hr) | Uporaba ave0010 za proizvodnju lijeka za liječenje dijabetes melitusa tip 2 | |
| Sen et al. | EDITORIAL (thematic issue: treatment and diagnosis of diabetes mellitus and its complication: advanced approaches) | |
| JP2017538705A5 (https=) | ||
| RU2014111821A (ru) | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа | |
| RU2013155474A (ru) | Ликсисенатид и метформин для лечения диабета типа 2 | |
| RU2013155473A (ru) | Фармацевтическая комбинация для применения для индуцирования потери массы тела у субъектов с диабетом 2 типа или/и для предотвращения набора массы тела у субъектов с диабетом 2 типа | |
| JP2014528901A5 (https=) | ||
| RU2013155480A (ru) | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа | |
| JP2013541576A5 (https=) | ||
| JP6438944B2 (ja) | インスリングラルギン／リキシセナチド固定比率製剤 | |
| JP2018509419A5 (https=) | ||
| JP2017014206A5 (https=) | ||
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| JP2020536121A5 (https=) | ||
| JP2014513121A5 (https=) | ||
| JP2014129405A5 (https=) | ||
| JP2016515123A5 (https=) | ||
| Alhomoud et al. | Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems | |
| JP2011105610A5 (https=) | ||
| Gray et al. | Late positive flecainide challenge test for Brugada syndrome | |
| RU2014150946A (ru) | Способ снижения веса | |
| WO2010132562A3 (en) | Transdermal delivery of metformin | |
| JP2008189679A5 (https=) | ||
| JP2016514142A5 (https=) |